Descrizione del progetto
Biomarcatori innovativi per stratificare i disturbi neuropsichiatrici
La classificazione dei disturbi neuropsichiatrici quali la schizofrenia, in cui la biologia alla base rimane relativamente sconosciuta, dipende principalmente da biomarcatori di neuroimaging e da endpoint clinici. L’utilizzo di biomarcatori quantitativi non solo contribuirà alla classificazione delle malattie ma favorirà inoltre le attività di sviluppo dei farmaci. Il progetto PRISM 2, finanziato dall’UE, trarrà profitto dalle conoscenze generate dal suo progetto predecessore PRISM 1 nell’ambito di biomarcatori diagnostici e legati alle funzionalità sociali per la schizofrenia e il morbo di Alzheimer, con lo scopo di ampliarlo ai principali disturbi depressivi. L’obiettivo è individuare biomarcatori attendibili per agevolare la diagnosi e il trattamento personalizzato dei disturbi neuropsichiatrici.
Obiettivo
The current nosology of neuropsychiatric disorders provides a pragmatic approach to diagnosis and treatment choice but lacks reference to quantitative biological underpinnings of disease. This weakness impedes innovative drug development. To test whether a quantitative biological approach to the understanding and classification of neuropsychiatric disorders is both feasible and useful the PRISM 1 consortium was formed by academics, SMEs, patient organizations, regulators, ECNP, and EFPIA partners. PRISM 1 has now successfully identified quantitative biological parameters related to diagnosis (Schizophrenia (SZ) and Alzheimer Disease (AD)) as well as to social functioning irrespective of diagnosis. From the relationships between social function, neuroimaging, and cognitive endpoints a new neurobiological framework has emerged now needing further validation. Genetic studies of social functioning outcomes revealed known and novel loci for this phenotype. In addition, a preclinical test battery was developed, based on homologs of the clinical paradigms, to allow effective back-translation and a deepening of our neurobiological knowledge. Finally, a novel digital tool for assessing social function provided a novel, objective characterization that transcended the initial diagnostic classification and the digital readouts were associated with other study parameters. To build on outcomes of PRISM 1, PRISM 2 has three objectives. First, to determine the reproducibility of the transdiagnostic and pathophysiological relationship between DMN integrity and social dysfunction in SZ and AD that emerged from PRISM 1 and determine its potential to generalise to Major Depressive Disorders. Second, to test the causality between the quantitative variation in DMN integrity and social dysfunction. Third, to translate and communicate project results to the benefit of stakeholders, such as regulators, patients and their families, and health care providers.
Campo scientifico
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
Parole chiave
Programma(i)
Argomento(i)
Invito a presentare proposte
H2020-JTI-IMI2-2020-22-single-stage
Vedi altri progetti per questo bandoMeccanismo di finanziamento
RIA - Research and Innovation actionCoordinatore
9712CP Groningen
Paesi Bassi